COUR Pharmaceuticals has secured $105 million in a Series A investment round co-led by Lumira Ventures and Alpha Wave Ventures.
The funds will be used to support the advancement of COUR’s myasthenia gravis (MG) and type 1 diabetes (T1D) product candidates into Phase IIa clinical trials.
The Roche Venture Fund, Pfizer (as part of the Pfizer Breakthrough Growth Initiative), Bristol Myers Squibb, Angelini Ventures, and the JDRF T1D Fund also contributed to the financing.
COUR Pharmaceuticals is a clinical-stage biotechnology company developing therapies to treat patients with autoimmune and inflammatory diseases. COUR’s therapies are based on its antigen-specific immune tolerance platform and are designed to reprogramme the immune system to address the underlying root cause of immune-mediated diseases.
Data from multiple clinical and preclinical programmes have demonstrated the ability of COUR’s product candidates to induce antigen-specific immune tolerance and have the potential to treat a wide range of autoimmune and inflammatory diseases.
As well as product candidates in MG and T1D, the company is also developing a product for coeliac disease in collaboration with Takeda Pharmaceuticals and primary biliary cholangitis with Ironwood Pharmaceuticals.
“The impressive syndicate of thought-leading investors and prominent strategic investors is a testament to COUR’s platform technology and our paradigm-changing potential for patients impacted by a variety of autoimmune diseases,” said John Puisis, Founder and Chief Executive Officer of COUR. “We are excited to have this support as we advance our pipeline and revolutionise antigen-specific immune tolerance while avoiding immune system suppression in our mission to potentially bring to market life changing therapies for patients.”